Krystal Biotech, Inc. KRYS R2K

Healthcare · Biotechnology · United States

https://www.krystalbio.com

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Market & Price

Market Cap

$9.11B

Current Price

$309.03

High / Low (52W)

$316.30 / $125.36

Beta

0.49

Valuation

Stock P/E

41.42

Industry PE

23.65

Forward P/E

30.66

PEG Ratio

Book Value

$43.37

Price to Book

7.13

P/S

21.83

EV/EBITDA

45.97

Dividend Yield

Profitability & Returns

ROCE

13.10%

ROE

19.90%

ROA

9.04%

Profit Margin

53.92%

Op Margin

46.14%

EPS (Latest Qtr)

$1.83

EPS (TTM)

$7.46

Balance Sheet & Liquidity

Debt/Equity

0.71

Quick Ratio

8.82

Current Ratio

9.46

Debt

$9.11M

Total Assets

$1.33B

Current Assets

$1.02B

Working Capital

$921.66M

Ownership

Promoter Holding

11.14%

Chg in Prom Hold

FII / Inst Holding

99.42%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$8.30B

Total Revenue (TTM)

$417.30M

EBITDA

$180.47M

Free Cash Flow

$137.49M

Operating Cash Flow

$250.28M

Shares Outstanding

29.48M

Gross Margin

94.17%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

82.11%

Revenue (YoY)

31.90%

Earnings (YoY)

52.50%

PROS

Excellent profit margin of 53.9%.
Profit CAGR of 82.1% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	KRYS Krystal Biotech, Inc. R2K	309.03	41.42	$9.11B	-	13.10%	19.90%	-	82.11%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	8.56M	45.25M	70.28M	-	-	88.18M	96.04M	97.80M	107.11M	116.36M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.03M	7.17M	4.26M	6.59M	6.32M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	83.16M	88.88M	93.54M	100.51M	110.03M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46.90M	49.57M	52.16M	56.24M	56.34M
Operating Income	-322.00K	-465.00K	-715.00K	-2.09M	-2.28M	-2.45M	-2.97M	-4.69M	-5.89M	-5.34M	-5.95M	-6.95M	-9.68M	-14.35M	-16.39M	-15.65M	-50.22M	-28.75M	-31.45M	-48.82M	-38.05M	-25.99M	-6.68M	8.57M	-	-	36.25M	39.31M	41.37M	44.27M	53.69M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	37.89M	40.85M	42.99M	46.03M	55.41M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43.60M	46.77M	47.97M	51.13M	61.44M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.86M	8.44M	-31.40M	-269.00K	5.51M
Net Income	-322.00K	-494.00K	-759.00K	-5.27M	-2.15M	-2.28M	-2.75M	-4.11M	-5.35M	-4.27M	-5.34M	-6.83M	-9.61M	-15.81M	-16.36M	-15.59M	-49.97M	-28.11M	-29.85M	-45.30M	-33.21M	80.75M	932.00K	15.57M	-	-	35.73M	38.33M	79.36M	51.40M	55.93M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-0.37	-0.49	-0.74	-0.74	-0.70	-1.99	-1.10	-1.17	-1.76	-1.25	2.79	0.03	0.53	-	-	1.20	1.29	2.66	1.70	1.83
R&D Expense	241.00K	319.00K	446.00K	1.35M	1.52M	1.52M	1.91M	3.17M	4.22M	3.88M	3.52M	3.64M	5.10M	6.20M	6.59M	6.08M	9.31M	10.89M	11.52M	12.29M	12.14M	10.63M	10.96M	15.58M	13.51M	-	14.26M	14.41M	14.59M	-	15.33M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	0	50.70M	290.51M	389.13M
Cost of Revenue	-	-	-	-	-	-	0	3.09M	20.06M	23.05M
Gross Profit	-	-	-	-	-	-	0	47.60M	270.45M	366.08M
Operating Expenses	-	-	-	-	-	-	120.20M	144.72M	167.21M	204.79M
Operating Income	-1.14M	-4.77M	-11.92M	-22.08M	-33.00M	-	-120.20M	-97.12M	103.25M	161.29M
EBITDA	-	-	-	-	-	-	-116.81M	-91.21M	109.96M	167.85M
Interest Expense	-	-	-	-	-	1.49M	0	0	-	-
Pretax Income	-	-	-	-	-	-	-139.97M	12.90M	95.36M	189.47M
Tax Provision	-	-	-	-	-	-	0	1.97M	6.20M	-15.36M
Net Income	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-	-139.97M	10.93M	89.16M	204.83M
Diluted EPS	-	-	-	-	-1.71	-	-5.49	0.39	3.00	6.84
R&D Expense	741.00K	3.21M	7.76M	15.62M	17.94M	27.88M	42.46M	46.43M	53.58M	58.05M

Compounded Sales Growth

5 Years:	-
1 Year:	31.90%

Compounded Profit Growth

5 Years:	82.11%
1 Year:	52.50%

Stock Price Performance

1 Year:	+145.34%
6 Months:	+42.43%
3 Months:	+12.11%
1 Month:	+18.88%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2016	Aug 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	2.18M	-	50.11M	116.12M	209.02M	310.84M	-	558.45M	818.36M	1.06B	1.33B
Current Assets	-	-	-	-	-	-	-	383.78M	587.91M	742.04M	1.02B
Cash & Equivalents	1.92M	-	49.59M	103.67M	187.51M	268.27M	-	161.90M	358.33M	344.87M	496.30M
Inventory	-	-	-	-	-	-	-	0	6.99M	26.51M	40.48M
Receivables	-	-	-	-	-	-	-	0	42.04M	104.75M	127.42M
Total Liabilities	1.89M	-	640.00K	2.89M	6.11M	18.76M	-	36.22M	39.71M	109.46M	114.23M
Current Liabilities	43.00K	-	640.00K	2.60M	3.33M	15.45M	-	28.85M	33.09M	102.00M	102.94M
Long Term Debt	-	4.25M	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	8.93M	8.09M	7.26M	9.34M
Total Equity	289.00K	-	49.47M	113.23M	202.91M	292.08M	-	522.23M	778.64M	946.38M	1.22B
Shares Outstanding	-	-	-	-	-	-	-	25.76M	28.24M	28.79M	29.19M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-9.45M	-18.69M	-26.08M	-	-100.57M	-88.80M	123.42M	200.87M
Investing Cash Flow	-	-	-10.32M	-4.99M	-11.18M	-	-114.08M	82.64M	-163.44M	-58.42M
Financing Cash Flow	-	-	73.85M	107.53M	118.02M	-	35.35M	202.75M	27.01M	8.71M
Capital Expenditure	-15.00K	-210.00K	-2.23M	-6.40M	-14.84M	-	-52.98M	-11.80M	-4.24M	-11.95M
Free Cash Flow	-	-	-11.68M	-25.09M	-40.93M	-	-153.55M	-100.60M	119.18M	188.91M
Net Change in Cash	-	-	-	-	-	-	-179.31M	196.58M	-13.01M	151.15M

Ratios (Annual)

Figures in %.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	93.9%	93.1%	94.1%
Operating Margin %	-	-	-	-	-	-	-	-191.6%	35.5%	41.5%
Net Margin %	-	-	-	-	-	-	-	21.6%	30.7%	52.6%
ROE %	-397.9%	-16.0%	-9.6%	-9.4%	-11.0%	-	-26.8%	1.4%	9.4%	16.8%
ROCE %	-53.4%	-9.6%	-10.5%	-10.7%	-11.2%	-	-22.7%	-12.4%	10.8%	13.1%

Shareholding Pattern

Insiders

11.14%

Institutions

99.42%

Public Float

111.89%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	14.84%	4.37M	$1.35B
2	Blackrock Inc.	13.37%	3.94M	$1.22B
3	Avoro Capital Advisors LLC	9.80%	2.89M	$892.75M
4	Vanguard Portfolio Management LLC	4.94%	1.46M	$450.17M
5	State Street Corporation	4.46%	1.31M	$406.20M
6	Vanguard Capital Management LLC	3.95%	1.17M	$360.12M
7	Soleus Capital Management, L.P.	3.91%	1.15M	$356.34M
8	Capital World Investors	2.80%	824.72K	$254.86M
9	Redmile Group, LLC	2.28%	673.50K	$208.13M
10	Geode Capital Management, LLC	2.18%	643.98K	$199.01M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KRYS

No recent headlines available.

KRYS · Healthcare